Skip to main content

Table 2 Micropaticles and laboratory data after treatment in OR group and PD group

From: Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles

Variables OR (n = 60) PD (n = 26) P
Neutrophils, ×109/L, median(IQR) 3.62 [2.70,4.50] 4.30 [2.93,5.35] 0.232#
Platelets, ×109/L, median(IQR) 205 [154,258] 196 [160,281] 0.807#
NLR, median(IQR) 2.43 [1.62,3.23] 3.37 [1.75,7.04] 0.029#
LDH, U/L, median(IQR) 166 [142,200] 188 [169,240] 0.004#
CEA, ng/ml, median(IQR) 2.85 [1.95,12.76] 8.72 [3.29,50.13] 0.026#
CYFRA-211, ng/ml, median(IQR) 3.15 [2.14,4.08] 4.54 [3.30,8.11] < 0.0001#
SCC, ng/ml, median(IQR) 1.10 [0.93,1.58] 1.05 [0.68,1.93] 0.491#
Micropaticals, events/μL, median(IQR)
 total MPs 1975 [1090,3120] 3590 [1492,4405] 0.006#
 NMPs 118 [66,229] 248 [116,338] 0.002#
 PMPs 56 [31,109] 157 [93,282] <0.0001#
  1. NLR neutrophil-lymphocyte ratio, LDH lactate dehydrogenase, CEA carcino-embryonic antigen, CYFRA-211 Cytokeratin 19 fragment, SCC Squamous cell carcinoma antigen, MPs microparticals, NMPs neutrophil-derived microparticals, PMPs platelet-derived microparticles
  2. #Mann-Whitney U test